A busy intersection: Ethics and policy in cell and gene therapies

Commercializing Living Therapies with CCRM

Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future.

Featuring:

Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University

Siofradh McMahon, Director, Clinical Translation and Regulatory Affairs, CCRM

Join guests for a discussion about the responsibilities of the regenerative medicine industry, exploring how ethics can and should be embedded into the world’s emerging regulatory frameworks for cell and gene therapies.

Are kneejerk, fear-based reactions influencing the regulatory environment? How can international compliance be ensured when some industries working on genetically modified organisms, such as agriculture, are less tightly regulated than therapeutics? Is the conversation around emerging therapies unbalanced, focusing too much on benefits and not enough on risks, encouraging patients to demand access to unproven, risky therapies? Listen to find out.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.